Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Overview of attention for article published in Einstein (São Paulo), February 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (70th percentile)

Mentioned by

policy: 2 policy sources

Readers on

mendeley: 50 Mendeley

Summary Policy documents

So far, Altmetric has seen 2 policy documents that reference this research output.

Enzalutamide for treating hormone-sensitive metastatic prostate cancer : Committee papers

Cited by National Institute for Health and Care Excellence on 07 Jul 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Abiraterone Acetate for Metastatic Castrate Sensitive Prostate Cancer

Cited by Canadian Agency for Drugs and Technologies in Health on 26 May 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.